The UK's Vectura has blueprinted its late-stage plans for two key drug programs.
The experimental smoker's lung drug NVA237 will start a pivotal Phase III trial in June. A separate therapy that combines NVA237 with Novartis's QAB149 should begin Phase III in the fourth quarter. The launch of the two late-stage trials will trigger two milestone payments from Novartis worth $15 million.
Vectura's shares were also buoyed this morning by news that it posted more annual revenue than analysts had expected along with a smaller loss than the market expected.
- read the report from the Guardian